Company news

Panbela Therapeutics, Inc. news in 2024

Panbela Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Panbela Provides Business Update and Reports Q3 2024 Financial Results

November 13, 2024

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

October 30, 2024

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

September 23, 2024

Panbela Provides Business Update and Reports Q2 2024 Financial Results

August 12, 2024

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

July 29, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

June 23, 2024

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

June 9, 2024

Panbela Provides Business Update and Reports Q1 2024 Financial Results

May 14, 2024

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

May 5, 2024

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

April 30, 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

April 29, 2024

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

April 21, 2024

OTC Markets Group Welcomes New OTCQB Companies – April 22

April 22, 2024

Panbela Announces Poster Presentation at American Association for Cancer Research:

April 17, 2024

Panbela Announces Transfer to OTCQB Market

April 15, 2024

Calls in 2024

Decks in 2024